RxDoctor Payments Data

Manuel Cruz, MD

Nephrology · Manati, PRNPI 1720132988

Payments from drug & device makers

$1,335in general payments, 2019–2025

Across 17 payments — averaging $78.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cormedix Inc.$261
  • GSK$157
  • Nxstage Medical, Inc.$145
  • Bayer$142
  • Mallinckrodt Hospital Products Inc.$140
  • Fresenius USA Marketing, Inc.$138
  • plus $352 from 5 others

What the payments were for

  • Travel & lodging$26120%
  • Food & beverage$97473%
  • Education$1007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,335 in reported general payments places this provider in the 40th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$50,241
Medicare patients
67
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol251$181,206
LokelmaSodium Zirconium Cyclosilicate252$118,646
Sevelamer Carbonate367$59,526
Lanthanum Carbonate40$34,954
Calcium Acetate203$24,477
JardianceEmpagliflozin36$23,451
TradjentaLinagliptin27$20,521
KerendiaFinerenone24$18,634
EliquisApixaban17$9,994
JanuviaSitagliptin Phosphate13$9,779
RetacritEpoetin Alfa-Epbx14$7,533
LantusInsulin Glargine,hum.Rec.Anlog64$5,301
Gentamicin Sulfate58$3,465
Midodrine Hcl35$2,614
Allopurinol277$2,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$142$18,63424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Manati

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →